$ILMN +6.76% Breaks Higher as UBS Sets a $260 Target
$Illumina(ILMN)$
$Illumina (ILMN) Surged +6.76% to $222.29: Genomic Leader Powers Toward All-Time Highs, $260 Target in Sight
Latest Close Data ILMN closed at $222.29, up +6.76% (+$14.08), just 4.1% below its 52-week high of $231.81. Intraday swing reached 9.06%, with the stock trading up to $226.76 before easing.
Core Market Drivers UBS upgraded ILMN from Neutral to Buy with a Street-high $260 target, up from $135. S&P Dow Jones confirmed ILMN joins the S&P 500 on September 21, triggering forced index-fund accumulation. RBC noted clinical sequencing revenue should sustain double-digit growth as competitive fears fade.
Technical Analysis Volume blasted to 3.15M shares, a 1.69× volume ratio versus average. MACD remains in bearish territory (DIF 3.37 vs. DEA 4.45, histogram -2.17) but is compressing sharply, signaling a pending bullish crossover. RSI(6) jumped to 66.5, breaking decisively above the 50 midpoint from 36.3 just four sessions ago. RSI(12) at 60.5 confirms strengthening momentum without being overbought.
Key Price Levels Primary support sits at $208.21 (yesterday's close, now gap-fill zone). Strong resistance is the 52-week high at $231.81. Immediate pivot: $217.80 — a hold above this prior resistance-turned-support keeps the breakout structure intact.
Valuation Perspective P/E (TTM) of 41.4× trails the 52-week average forward P/E of 60.8× substantially. P/S of 7.5× and P/B of 11.8× reflect premium growth pricing, yet forward P/E of 38.9× remains below the +1σ historical band of 120.1×. ROE stands at a robust 32.3%.
Analyst Targets Nineteen analysts cover ILMN with a mean target of $201.27, ranging $113–$260. Consensus splits: 5 Strong Buy, 7 Buy, 7 Hold, 2 Underperform, 1 Sell.
Weekly Outlook Expect consolidation within $215–$232 as S&P 500 inclusion approaches. A daily close above $231.81 opens the path toward $245–$250 post-inclusion drift. Failure to hold $208 would invalidate the breakout and target the $195–$200 gap fill.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Markets involve risk; past performance does not guarantee future results. 📉📈
🎯 $Illumina (ILMN) Options Strategy：Bull Call Spread
-
Underlying: ILMN (Illumina)
-
View: Bullish breakout with momentum — UBS upgrade + S&P 500 inclusion catalyst; RSI(6) at 66.5, MACD compression signaling bullish crossover
-
Strategy Type: Debit spread / Defined-risk directional long
-
Option Contract Portfolio:
-
Buy to Open: 1 × ILMN 2026-10-16 $220 Call @ ~$14.65 debit
-
Sell to Open: 1 × ILMN 2026-10-16 $240 Call @ ~$6.20 credit
-
-
Max Gain & Loss:
-
Max Gain: ($240 − $220) × 100 − Net Debit = $2,000 − $845 = $1,155
-
Max Loss: Net Debit = $845
-
-
Initial Cost/Credit: Net Debit ≈ $8.45 per share ($845 total)
Markets are always moving - and sometimes, the best move is knowing what works for you.
With Treasury yields, oil prices and rate expectations keeping markets on edge this week, investors are once again thinking carefully about where to position next. There’s no one-size-fits-all choice in investing — and the same goes for Tiger Merch. This month’s hot picks are in, featuring the Tiger Toiletry Bag, Universal Travel Adapter, Tiger Umbrella and more favourites chosen by fellow Tigers.
Explore the Monthly Hot Picks in Tiger Coin Mall, now 12% OFF for a limited time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
